Juno Therapeutics Gmbh

Pascal Beauchesne

Mark L Bonyhadi

Chris Ramsborg

Calvin Chan

Christopher Glen Ramsborg

Ryan P Larson

Nathan K Yee

Clinton Weber

Mary Mallaney

Jeff D Smith

Mark J Gilbert

He Li

Valerie Odegard

Brian Christin

Tom Kowski

Kathryn Lindsay Pollock

Claire L Sutherland

Ryan L Crisman

Andrew W Walker

Kedar Himanshu Dave

Sarah Y Lee

John Matthew Wesner

Michael Gerard Covington

Richard James Getto, Jr

James Boyd Whitmore

Travis Beckett

Samuel Charles Blackman

Nathaniel Chartrand

Nathaniel Lambert

Mel Davis-pickett

Nikolaus Sebastian Trede

The present disclosure relates in some aspects to methods, cells, and compositions for preparing cells and compositions for genetic engineering and cell therapy. Provided in some embodiments are streamlined cell preparation methods, e.g., for isolation, processing, incubation, and genetic engineering of cells and populations of cells. Also provided are cells and compositions produced by the methods and methods of their use. The cells can include immune cells, such as T cells, and generally include a plurality of isolated T cell populations or types. In some aspects, the methods are capable of preparing of a plurality of different cell populations for adoptive therapy using fewer steps and/or resources and/or reduced handling compared with other methods.

Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy

The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the incubation and/or the cultivation is performed in the presence of recombinant IL-2. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.

Process for generating therapeutic compositions of engineered cells

Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.

Determining toxicity risk in CAR T-cell therapy

Growing community of inventors

Seattle, WA, United States of America

Pascal Beauchesne